Indium (111In) biciromab

Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]

Indium (111In) biciromab
Monoclonal antibody
TypeFab' fragment
SourceMouse
TargetFibrin II, beta chain
Clinical data
Trade namesFibriScint
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Withdrawn
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NY (what is this?)  (verify)

References

  1. King, David J.; John R. Adair (1999). "Recombinant antibodies for the diagnosis and therapy of human disease". Current Opinion in Drug Discovery & Development. 2 (2): 112. ISSN 1367-6733.
  2. Answers.com: Centocor Ortho Biotech Products, L.P.
  3. DiagnosticImaging.com: Centocor withdraws imaging agent applications


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.